Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Current Assets: 2010-2024

Historic Current Assets for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $3.3 million.

  • China Pharma Holdings' Current Assets fell 37.70% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 37.70%. This contributed to the annual value of $3.3 million for FY2024, which is 45.47% down from last year.
  • As of FY2024, China Pharma Holdings' Current Assets stood at $3.3 million, which was down 45.47% from $6.0 million recorded in FY2023.
  • China Pharma Holdings' 5-year Current Assets high stood at $9.1 million for FY2021, and its period low was $3.3 million during FY2024.
  • Its 3-year average for Current Assets is $5.1 million, with a median of $6.0 million in 2022.
  • Per our database at Business Quant, China Pharma Holdings' Current Assets surged by 70.87% in 2021 and then tumbled by 45.47% in 2024.
  • Over the past 5 years, China Pharma Holdings' Current Assets (MRY) stood at $5.3 million in 2020, then surged by 70.87% to $9.1 million in 2021, then tumbled by 34.41% to $6.0 million in 2022, then grew by 0.54% to $6.0 million in 2023, then crashed by 45.47% to $3.3 million in 2024.
  • Its last three reported values are $3.3 million in FY2024, $6.0 million for FY2023, and $6.0 million during FY2022.